• Product NameCBL0137
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityCBL0137 is a metabolically stable curaxin that activates p53 with an EC50 value of 0.37 ?M and inhibits NF-κB with an EC50 of 0.47 ?M.1 It functionally inactivates the facilitates chromatin transcription complex (FACT), driving the effects on p53 and NF-κB and promoting cancer cell death.1 CBL0137 has broad anticancer activity in mice when administered orally, eradicates drug-resistant cancer stem cells, and potentiates efficacy of gemcitabine (Item No. 11690) in preclinical models of pancreatic cancer.
• Target Namep53 activator;NF-κB inhibitor
• CAS No. 1197996-80-7
• Calculated MW 336.435
• Formulation C21H24N2O2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:cancer
  SMILES:CC(C)NCCN1C2=C(C=C(C=C2)C(=O)C)C3=C1C=CC(=C3)C(=O)C
  Pathways:Apoptosis;NF-Kb
  Receptor:p53;NF-κB
  Boling pt:
  Melting pt:
  Solubility:N/A
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1.Gasparian, AV. et al. Curaxins: Anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. Sci.Transl.Med. 3(95), (2011).

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting